Your browser is no longer supported. Please, upgrade your browser.
Settings
ISEE [NASD]
IVERIC bio, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own0.10% Shs Outstand93.41M Perf Week7.89%
Market Cap1.80B Forward P/E- EPS next Y-1.13 Insider Trans-21.53% Shs Float59.20M Perf Month81.91%
Income-107.80M PEG- EPS next Q-0.29 Inst Own85.80% Short Float20.84% Perf Quarter187.36%
Sales- P/S- EPS this Y18.20% Inst Trans5.48% Short Ratio2.22 Perf Half Y205.41%
Book/sh1.49 P/B11.74 EPS next Y6.70% ROA-53.60% Target Price17.00 Perf Year228.33%
Cash/sh1.55 P/C11.29 EPS next 5Y- ROE-60.50% 52W Range4.96 - 18.01 Perf YTD153.26%
Dividend- P/FCF- EPS past 5Y17.90% ROI- 52W High-10.77% Beta1.50
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low223.99% ATR1.15
Employees66 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)66.20 Volatility6.13% 8.33%
OptionableYes Debt/Eq0.00 EPS Q/Q0.30% Profit Margin- Rel Volume0.72 Prev Close17.50
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume5.57M Price16.07
Recom1.70 SMA2018.96% SMA5046.21% SMA200109.86% Volume1,925,986 Change-8.17%
Sep-10-21Initiated Stifel Buy $22
Aug-19-21Initiated H.C. Wainwright Buy $20
Aug-13-20Initiated Credit Suisse Outperform $13
Jan-24-20Initiated Cowen Outperform $15
Jan-07-20Initiated Wedbush Outperform
Sep-13-21 05:07AM  
Sep-10-21 04:05PM  
12:23PM  
11:39AM  
10:58AM  
10:40AM  
07:02AM  
Sep-02-21 08:00AM  
Aug-18-21 08:40AM  
Aug-10-21 08:00AM  
Aug-04-21 04:05PM  
06:30AM  
Aug-03-21 08:00AM  
Aug-01-21 05:36AM  
Jul-28-21 08:00AM  
Jul-26-21 07:30AM  
Jul-19-21 07:30AM  
Jul-14-21 06:20AM  
Jul-13-21 07:17AM  
Jul-12-21 10:09PM  
04:07PM  
03:21PM  
08:34AM  
Jul-06-21 07:29AM  
06:00AM  
Jun-18-21 09:26AM  
07:00AM  
Jun-09-21 07:30AM  
May-05-21 11:01PM  
06:30AM  
06:15AM  
May-04-21 08:00AM  
May-02-21 05:39AM  
Apr-28-21 08:00AM  
Apr-19-21 03:23PM  
Apr-06-21 11:16AM  
Apr-05-21 06:45AM  
Apr-01-21 05:30PM  
Mar-16-21 08:00AM  
Mar-11-21 08:17AM  
Mar-03-21 01:00PM  
06:30AM  
06:15AM  
Mar-02-21 08:00AM  
Feb-25-21 08:00AM  
Feb-24-21 08:00AM  
Feb-16-21 01:27PM  
Feb-08-21 10:11AM  
Jan-05-21 08:00AM  
Dec-17-20 08:00AM  
Dec-04-20 08:00AM  
Nov-03-20 07:45AM  
Nov-02-20 07:00AM  
Oct-29-20 08:00AM  
Oct-26-20 11:55PM  
08:00AM  
Oct-16-20 08:46AM  
Oct-02-20 08:00AM  
Sep-15-20 01:02AM  
Sep-03-20 08:00AM  
Sep-02-20 08:00AM  
Sep-01-20 08:45AM  
Aug-05-20 07:00AM  
Aug-04-20 08:00AM  
Aug-03-20 06:55PM  
Jul-29-20 08:00AM  
Jul-27-20 03:49PM  
Jul-17-20 10:36AM  
Jul-16-20 08:00AM  
Jul-03-20 06:31AM  
Jun-30-20 07:30AM  
Jun-22-20 05:16PM  
Jun-18-20 12:50AM  
Jun-17-20 04:01PM  
Jun-16-20 09:39AM  
Jun-15-20 06:15AM  
Jun-14-20 04:00PM  
Jun-02-20 07:30AM  
May-27-20 08:00AM  
May-26-20 10:43AM  
May-21-20 08:40AM  
May-13-20 09:49AM  
May-12-20 10:02AM  
May-11-20 08:00AM  
May-06-20 07:00AM  
May-04-20 08:00AM  
Apr-28-20 08:00AM  
Apr-03-20 08:00AM  
Apr-02-20 08:00AM  
Mar-23-20 04:01PM  
Mar-18-20 11:39AM  
08:00AM  
Mar-04-20 08:41AM  
Mar-03-20 08:00AM  
Feb-27-20 07:00AM  
Feb-26-20 08:00AM  
Feb-20-20 08:00AM  
Jan-13-20 08:00AM  
Jan-07-20 12:26PM  
Dec-23-19 07:58PM  
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dugel PravinEVP, Chief Strategy & BusinessApr 05Sale6.3428,301179,42841,699Apr 05 09:30 PM
Westby KeithSVP & COOJan 04Sale6.8511,87581,34486,466Jan 05 04:05 PM
Carroll David FrancisSVP, CFO and TreasurerJan 04Sale6.8511,87581,34480,165Jan 05 04:02 PM
Westby KeithSVP & COODec 14Sale7.164,52732,41365,841Dec 15 02:49 PM
GUYER DAVID RExecutive ChairmanDec 14Sale7.169,27066,37370,113Dec 15 02:48 PM
Westby KeithSVP & COODec 10Sale6.963,67625,58557,868Dec 11 09:04 PM
GUYER DAVID RExecutive ChairmanDec 10Sale6.969,60266,83062,183Dec 11 08:59 PM